Menu
The ALL ALS Consortium is spearheaded by a dedicated team of researchers, coordinators, and collaborators from across the nation, all united in the fight against ALS.
Dr. Berry and Dr. Bowser head the research efforts of the ALL ALS Consortium and are Primary Investigators on the ASSESS ALL ALS and PREVENT ALL ALS Study protocols.
Neurological Clinical Research Institute | Massachusetts General Hospital
ALL ALS East Coordinating Center
Dr. James Berry is a licensed neurologist who specializes in amyotrophic lateral sclerosis (ALS) and holds several key roles: Winthrop Family Scholar in ALS Sciences, Director of the MGH multidisciplinary ALS clinic, and Chief of the Division of ALS and Motor Neuron Diseases. He has expanded the clinic’s reach through initiatives like the ALS House Call and video televisit programs.
As a researcher, Dr. Berry designs and manages ALS trials at MGH and other centers nationwide, focusing on identifying ALS biomarkers in blood and spinal fluid, particularly those related to abnormal inflammation. He collaborates with global researchers and is developing mobile health and digital methods to improve understanding of ALS and accelerate therapy development.
Additionally, Dr. Berry directs the MGH Neurological Clinical Research Institute and the Mass General Brigham Neurodegenerative Clinical Research Fellowship. He contributes to the Massachusetts ALS Registry, CDC/ATSDR National ALS Registry, and Biorepository Expert Panels, and leads the NEALS Biorepository and Technology in ALS subcommittee.
Barrow Neurological Institute | Dignity Health St. Joseph’s Hospital and Medical Center
ALL ALS West Coordinating Center
Robert Bowser, PhD, is the Chief Scientific Officer and John P. and Betty Van Denburgh Chair for Neuromuscular Disease at Barrow Neurological Institute, where he also serves as the Chair of the Department of Translational Neuroscience.
A leader in ALS research, Dr. Bowser is known for his groundbreaking work in discovering and validating biomarkers for ALS and other neurodegenerative diseases. These biomarkers are crucial for diagnosing diseases, predicting progression, and assessing drug treatments. His lab explores neurodegeneration mechanisms, develops new drug delivery technologies, and examines gene expression in human tissue samples.
Dr. Bowser also oversees research at Barrow Neurological Institute and St. Joseph’s Hospital, co-directs national biorepositories of ALS biofluids and post-mortem tissues, and participates in numerous clinical trials. His work has earned him several awards, including the Sheila Essey Award for ALS research. His research is funded by NIH, the Department of Defense, Target ALS, and the ALS Association.
The ALL ALS Consortium and all related studies are funded by the National Institutes of Health (NIH), Grant # 1OT2NS136938 and 1OT2NS136939.